SIRPA and hematopoietic and lymphoid cell neoplasm: Anti-CD47 mAbs and selective SIRPα blockers had similar efficacy in hematologic cancers, with ORRs of 29.8% and 23.0%, respectively (p=0.48, DCR p=0.69).